Lung cancer patients with COVID-19 in Spain: GRAVID study DOI Creative Commons
Mariano Provencio, José María Mazarico Gallego, Antonio Calles

et al.

Lung Cancer, Journal Year: 2021, Volume and Issue: 157, P. 109 - 115

Published: May 13, 2021

Patients with cancer may be at increased risk of more severe COVID-19 disease; however, prognostic factors are not yet clearly identified. The GRAVID study aimed to describe clinical characteristics, outcomes, and predictors poor outcome in patients lung COVID-19.Prospective observational that included medical records PCR-confirmed diagnosis across 65 Spanish hospitals. primary endpoint was all-cause mortality; secondary endpoints were hospitalization admission intensive care units (ICU).A total 447 a mean age 67.1 ± 9.8 years analysed. majority men (74.3 %) current/former smokers (85.7 %). NSCLC the most frequent type (84.5 %), mainly as adenocarcinoma (51.0 stage III metastatic or unresectable disease (79.2 Nearly 60 % receiving anticancer treatment, mostly first-line chemotherapy. Overall, 350 (78.3 hospitalized for 13.4 11.4 days, 9 (2.0 admitted ICU 146 (32.7 died. Advanced use corticosteroids treat during mortality. Hospitalized, non-end-of-life lymphocytopenia high LDH had an death. Severity correlated higher mortality, admission, mechanical ventilation rates.Mortality rate among treated hospitalization, while therapy associated Tailored approaches warranted ensure effective management minimizing exposure SARS-CoV-2.

Language: Английский

Clinical applications of plasma proteomics and peptidomics: Towards precision medicine DOI
Bo He, Zhao Huang, Canhua Huang

et al.

PROTEOMICS - CLINICAL APPLICATIONS, Journal Year: 2022, Volume and Issue: 16(6)

Published: May 1, 2022

In the context of precision medicine, disease treatment requires individualized strategies based on underlying molecular characteristics to overcome therapeutic challenges posed by heterogeneity. For this purpose, it is essential develop new biomarkers diagnose, stratify, or possibly prevent diseases. Plasma an available source that greatly reflects physiological and pathological conditions body. An increasing number studies are focusing proteins peptides, including many involving Human Proteome Project (HPP) Organization (HUPO), proteomics peptidomics techniques emerging as critical tools for developing novel medicine preventative measures. Excitingly, plasma toolbox exhibits a huge potential studying pathogenesis diseases (e.g., COVID-19 cancer), identifying valuable improving clinical management. However, enormous complexity wide dynamic range makes proteome profiling challenging. Herein, we summarize recent advances in with focus their roles cancer research, aiming emphasize significance applications medicine.

Language: Английский

Citations

37
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer DOI Creative Commons
Vivek Naranbhai, Kerri St. Denis, Evan C. Lam

et al.

Cancer Cell, Journal Year: 2022, Volume and Issue: 40(1), P. 103 - 108.e2

Published: Jan. 1, 2022

Language: Английский

Citations

34
Efficacy and Safety Profile of COVID-19 Vaccine in Cancer Patients: A Prospective, Multicenter Cohort Study DOI
Ayşe İrem Yasin, Sabin Göktaş Aydın, Bilge Sümbül

et al.

Future Oncology, Journal Year: 2022, Volume and Issue: 18(10), P. 1235 - 1244

Published: Jan. 27, 2022

To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate factors affecting seropositivity.

Language: Английский

Citations

30
Impact of the COVID-19 pandemic on reported cancer diagnoses in Bavaria, Germany DOI Creative Commons
Sven Voigtländer,

Amir Hakimhashemi,

Nina Grundmann

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2023, Volume and Issue: 149(10), P. 7493 - 7503

Published: March 24, 2023

Abstract Purpose The aim of our study was to explore the impact COVID-19 pandemic on reported cancer cases in Bavaria, Germany, by comparing pre-pandemic (March 2019 February 2020) and period 2020 2021). Methods Data incident were retrieved from Bavarian Cancer Registry (until 22nd April 2022). We included patients with malignant situ neoplasms pathology departments consistent reporting. calculated number during 95% confidence intervals (CI) Bonferroni correction (α = 0.0018) based a Poisson approach. stratified for malignancy (malignant, situ), tumor site, month year. Results available 30 out 58 (51.7%) Bavaria. Incident dropped 42,857 39,980 (− 6.7%; CI − 8.7%, 4.7%). Reductions higher colon, rectum, skin/melanoma as well liver (> 10.0% reduction) less breast (4.9% reduction). No case reductions observed pancreas, esophagus, ovary, cervix. Percent changes largest 20.9%; 24.7%, 16.8%) January 2021 25.2%; 28.8%, 21.5%) compared previous Declines tended be larger neoplasms. Conclusion Detection diagnosis substantially reduced pandemic. Potential effects, e.g. stage shift tumors or an increase mortality, need monitored.

Language: Английский

Citations

17
Lung cancer patients with COVID-19 in Spain: GRAVID study DOI Creative Commons
Mariano Provencio, José María Mazarico Gallego, Antonio Calles

et al.

Lung Cancer, Journal Year: 2021, Volume and Issue: 157, P. 109 - 115

Published: May 13, 2021

Patients with cancer may be at increased risk of more severe COVID-19 disease; however, prognostic factors are not yet clearly identified. The GRAVID study aimed to describe clinical characteristics, outcomes, and predictors poor outcome in patients lung COVID-19.Prospective observational that included medical records PCR-confirmed diagnosis across 65 Spanish hospitals. primary endpoint was all-cause mortality; secondary endpoints were hospitalization admission intensive care units (ICU).A total 447 a mean age 67.1 ± 9.8 years analysed. majority men (74.3 %) current/former smokers (85.7 %). NSCLC the most frequent type (84.5 %), mainly as adenocarcinoma (51.0 stage III metastatic or unresectable disease (79.2 Nearly 60 % receiving anticancer treatment, mostly first-line chemotherapy. Overall, 350 (78.3 hospitalized for 13.4 11.4 days, 9 (2.0 admitted ICU 146 (32.7 died. Advanced use corticosteroids treat during mortality. Hospitalized, non-end-of-life lymphocytopenia high LDH had an death. Severity correlated higher mortality, admission, mechanical ventilation rates.Mortality rate among treated hospitalization, while therapy associated Tailored approaches warranted ensure effective management minimizing exposure SARS-CoV-2.

Language: Английский

Citations

36